Idera Pharmaceuticals Expands Pipeline By Initiating Clinical Development Of Proprietary TLR Antagonist Candidate IMO-9200
October 14, 2014 at 08:07 AM EDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients ...
